Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by tums1on Jun 03, 2010 7:09am
440 Views
Post# 17153302

Some positive ratings are a good sign

Some positive ratings are a good sign


Best-Rated Canadian Stocks Updated May 30, 2010

https://www.nasd100.com/2010/05/bestrated-canadian-stocks-updated-may-30-2010.html

Below are the best-rated Canadian stocks based on average Wall Street analyst ratings. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). Then the average is calculated to represent the overall rating of a stock.

Ranking  |  Company (Ticker)  |  Average Rating Value  |  Average Rating

1 AlarmForce Industries (TSE:AF) 1.00  Strong Buy
2 Amorfix Life Sciences Ltd. (TSE:AMF) 1.00  Strong Buy
3 Aquila Resources Inc. (TSE:AQA) 1.00  Strong Buy
4 Aeroquest International Limited (TSE:AQL) 1.00  Strong Buy
5 Bioniche Life Sciences (TSE:BNC) 1.00  Strong Buy
6 Coro Mining Corp. (TSE:COP) 1.00  Strong Buy
7 The Cash Store Financial Services Inc. (TSE:CSF) 1.00  Strong Buy
8 Chartwell Technology Inc. (TSE:CWH) 1.00  Strong Buy
9 Continental Precious Minerals Inc (TSE:CZQ) 1.00  Strong Buy
10 Electrovaya Inc. (TSE:EFL) 1.00  Strong Buy
11 Energy Fuels Inc. (TSE:EFR) 1.00  Strong Buy
12 Enterra Energy Trust (TSE:ENT.UN) 1.00  Strong Buy
13 Firan Technology Group Corp. (TSE:FTG) 1.00  Strong Buy
14 Helix Biopharma Corp. (TSE:HBP) 1.00  Strong Buy
15 Hammond Power Solutions Inc. (TSE:HPS.A) 1.00  Strong Buy
Bullboard Posts